This activity is expired and is no longer available for CME credit.


Shifting the Paradigm in Multiple Sclerosis Treatment by Targeting New Pathways

Release Date: 11/17/2014Expiration Date: 11/16/2015
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks and destroys myelin and myelinated axons in the CNS and is the most common nontraumatic cause of neurological disability, morbidity, and impairment in young adults. Approximately 400,000 Americans and over 2.5 million people worldwide are affected by MS. Proper staging and assessment of progression are critical to making appropriate decisions in determining clinical strategies. For clinicians who manage patients with MS, it is important to keep up to date with the latest treatment advances, their benefits, limitations, and optimal use so that they can provide the best outcomes for their patients. Treatments are now being designed that target the B-cell, and these targeted approaches may match or surpass current treatment modalities in terms of efficacy, while also reducing the risk of adverse effects. In this program, leading clinicians and researchers will discuss the latest thinking on approaches to monitoring progression and the latest data regarding targeted therapies that may improve clinical outcomes for patients with MS.